home / stock / meobf / meobf news

MEOBF News and Press, Mesoblast Ltd Ord

Stock Information
Company Name: Mesoblast Ltd Ord
Stock Symbol: MEOBF
Market: OTC
Website: mesoblast.com
Menu
MEOBF MEOBF Quote MEOBF Short MEOBF News MEOBF Articles MEOBF Message Board
Get MEOBF Alerts

News, Short Squeeze, Breakout and More Instantly...
MEOBF - Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical...
MEOBF - Mesoblast Limited (MESO) Q2 2026 Earnings Call Transcript

2026-02-27 02:27:52 ET Mesoblast Limited (MESO) Q2 2026 Earnings Call February 26, 2026 5:00 PM EST Company Participants Paul Hughes - Joint Company Secretary Silviu Itescu - Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director James O&#...

MEOBF - Ryoncil® Profits Underpinning Substantial Growth Pipeline

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended December 31, 2025 (H1 FY2026). FINANCIAL HIGHLIGHTS FO...

MEOBF - High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD

NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided data presented at the February 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTC...
MEOBF - Ryoncil® Net Revenues Increase for the Quarter to US$30M

NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the second fiscal quarter ended December 31, 2025. “This quarter was high...

MEOBF - Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment

NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on use of Ryoncil ® (remestemcel-L-rknd) since commercially available in March 2025 for the approved label...

MEOBF - FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy

NEW YORK, Jan. 18, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided feedback received from the U.S. Food & Drug Administration (FDA) on potential filing of a Biologics License Applicatio...
MEOBF - Ryoncil® Sales Increase 60% in December Quarter to US$35.1M

NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$35.1 million on Ryoncil ® (remestemcel-L-rknd) sales for the quarter ended December 31, 2025. 1...

MEOBF - Mesoblast Announces Changes to Board of Directors' Leadership Roles

NEW YORK, Jan. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that as foreshadowed at the recent Annual General Meeting the Board will undertake a number of changes in line with the C...

MEOBF - Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line

Mesoblast has option to draw down up to US$125 million by June 30, 2026 New facility does not encumber any of Mesoblast's material assets or intellectual property NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medi...
Next 10